From Covid-19 to Cancer: Curing Diseases With New Therapies

The transcript discusses Genentech's focus on therapeutics and international partnerships during the pandemic. It highlights the company's research on COVID-19 therapeutics, including emergency use authorizations and future management of the disease. Genentech's role in the fight against COVID-19, including partnerships with Regeneron, is detailed. The future of medicine, particularly in oncology, is explored, emphasizing the integration of biology and data analytics. Finally, the transcript addresses the challenges of drug affordability and the need for solutions that balance innovation and cost reduction.

What is the speaker's perspective on achieving herd immunity for COVID-19?

In what ways does the speaker suggest that the merging of biology and data analytics will impact medicine?

What challenges regarding drug affordability are highlighted in the discussion?